We are improving our search experience. To check which content you have full access to, or for advanced search, go back to the old search.

Search

Please fill in this field.

Search Results

Showing 81-100 of 9,849 results
  1. Molecular Pathways and Animal Models of Cardiomyopathies

    Cardiomyopathies are a heterogeneous group of disorders of the heart muscle that ultimately result in congestive heart failure. Rapid progress in...
    Buyan-Ochir Orgil, Enkhsaikhan Purevjav in Congenital Heart Diseases: The Broken Heart
    Chapter 2024
  2. Human Genetics of Cardiomyopathies

    The identification of a disease-causing variant in a patient diagnosed with cardiomyopathy allows for presymptomatic testing in at risk relatives....
    Arjan C. Houweling, Ronald H. Lekanne Deprez, Arthur A. M. Wilde in Congenital Heart Diseases: The Broken Heart
    Chapter 2024
  3. Clinical Presentation and Therapy of Atrioventricular Septal Defect

    Atrioventricular septal defects (AVSDs) consist of a number of cardiac malformations that result from abnormal development of the endocardial...
    Nikolaus A. Haas, David J. Driscoll, Silke Rickert-Sperling in Congenital Heart Diseases: The Broken Heart
    Chapter 2024
  4. Molecular Pathways and Animal Models of Semilunar Valve and Aortic Arch Anomalies

    The great arteries of the vertebrate carry blood from the heart to the systemic circulation and are derived from the pharyngeal arch arteries. In...
    Eleanor Gill, Simon D. Bamforth in Congenital Heart Diseases: The Broken Heart
    Chapter 2024
  5. Alzheimer’s Disease Prevention and Treatment Based on Population-Based Approaches

    The development of effective prevention and treatment strategies for Alzheimer’s disease (AD) and dementia is hindered by limited knowledge of the...
    Protocol 2024
  6. CSF N-Glycomics Using MALDI MS Techniques

    In this chapter, we will present the methodology currently applied in our laboratory for the structural elucidation of the cerebrospinal fluid (CSF)...
    Angela Messina, Donata Agata Romeo, ... Domenico Garozzo in Biomarkers for Alzheimer’s Disease Drug Development
    Protocol 2024
  7. CSF N-Glycomics Using High-Throughput UPLC-ESI Techniques in Alzheimer’s Disease

    In this chapter, we will present a high-throughput method applied in our laboratory for the structural elucidation of the cerebrospinal fluid (CSF)...
    Angela Messina, Rita Barone, ... Domenico Garozzo in Biomarkers for Alzheimer’s Disease Drug Development
    Protocol 2024
  8. In Silico Models to Validate Novel Blood-Based Biomarkers

    Biological validation of preliminary findings is a key prerequisite in biomarker discovery. In recent years, the development of advanced large-scale...
    Protocol 2024
  9. Mass Spectrometry-Based Metabolomics Multi-platform for Alzheimer’s Disease Research

    The integration of complementary analytical platforms is nowadays the most common strategy for comprehensive metabolomics analysis of complex...
    Álvaro González-Domínguez, Ana Sayago, ... Raúl González-Domínguez in Biomarkers for Alzheimer’s Disease Drug Development
    Protocol 2024
  10. High-Throughput Lipidomic and Metabolomic Profiling for Brain Tissue and Biofluid Samples in Neurodegenerative Disorders

    Recent research has revealed the potential of lipidomics and metabolomics in identifying new biomarkers and mechanistic insights for...
    Bonne M. Thompson, Giuseppe Astarita in Biomarkers for Alzheimer’s Disease Drug Development
    Protocol 2024
  11. Magnetic Resonance Spectroscopy (MRS) in Alzheimer’s Disease

    MRS is a noninvasive technique to measure different metabolites in the brain. Changes in the levels of certain metabolites can be used as surrogate...
    Nasim Sheikh-Bahaei, Michelle Chen, Ioannis Pappas in Biomarkers for Alzheimer’s Disease Drug Development
    Protocol 2024
  12. Analysis of Resting-State Functional Magnetic Resonance Imaging in Alzheimer’s Disease

    Alzheimer’s disease (AD) has been characterized by widespread network disconnection among brain regions, widely overlap** with the hallmarks of the...
    Ersin Ersözlü, Boris-Stephan Rauchmann in Biomarkers for Alzheimer’s Disease Drug Development
    Protocol 2024
  13. Measuring Size and Number Concentration of Metallic Nanoparticles Using spICP-MS

    This protocol describes how to measure the size and concentration of individual metallic nanoparticles using inductively coupled plasma-mass...
    Matthew Hansen, Jeffrey D. Clogston in Characterization of Nanoparticles Intended for Drug Delivery
    Protocol 2024
  14. Methods for Analysis of Nanoparticle Immunosuppressive Properties

    Adverse drug effects on immune system function represent a significant concern in the pharmaceutical industry, because 10–20% of drug withdrawal from...
    Edward Cedrone, Timothy M. Potter, ... Marina A. Dobrovolskaia in Characterization of Nanoparticles Intended for Drug Delivery
    Protocol 2024
  15. Evaluation of the Acute Anaphylactoid Reactogenicity of Nanoparticle-Containing Medicines and Vaccines Using the Porcine CARPA Model

    A small fraction, up to 10%, of people treated intravenously with state-of-the-art nanoparticulate drugs or diagnostic agents develop an acute...
    Protocol 2024
  16. Immunophenoty**, Part I: Instrument Calibration and Reagent Qualification for Immunophenoty** Analysis of Human Peripheral Blood Mononuclear Cell Cultures

    Nanoparticles are increasingly used in biomedical applications to influence the way the immune system reacts to tumors and infectious disease-causing...
    Hannah S. Newton, Jenny Zhang, Marina A. Dobrovolskaia in Characterization of Nanoparticles Intended for Drug Delivery
    Protocol 2024
  17. Ion Quantitation in Liposomal Products Using RP-HPLC with Charged Aerosol Detection

    Ion concentration in liposomal drugs is important for drug stability and drug release profile. However, quantifying ion concentration in liposomal...
    Protocol 2024
  18. Detection of Antigen Presentation by Murine Bone Marrow–Derived Dendritic Cells After Treatment with Nanoparticles

    Nanoparticles are frequently considered in vaccine applications due to their ability to co-deliver multiple antigens and adjuvants to...
    En** Hong, Marina A. Dobrovolskaia in Characterization of Nanoparticles Intended for Drug Delivery
    Protocol 2024
  19. Detection of Pre-Existing Antibodies to Polyethylene Glycol and PEGylated Liposomes in Human Serum

    Polyethylene glycol, or PEG, is common in consumer products, over-the-counter medications, food, and pharmaceutical products. Concerns about PEG...
    Barry W. Neun, Marina A. Dobrovolskaia in Characterization of Nanoparticles Intended for Drug Delivery
    Protocol 2024
  20. Detection of Intracellular Complement Activation by Nanoparticles in Human T Lymphocytes

    The complement system is complex and includes two main components: the systemic or plasma complement and the so-called intracellular complement or...
    Anna Ilinskaya, Ankit Shah, ... Marina A. Dobrovolskaia in Characterization of Nanoparticles Intended for Drug Delivery
    Protocol 2024
Did you find what you were looking for? Share feedback.